Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDUFA III Deal Sets FY 2003 User Fee Funding Lower Than Bush Budget

This article was originally published in The Tan Sheet

Executive Summary

FDA and industry's negotiated PDUFA III user fees reflect a lower budget increase than originally proposed by the Bush Administration

You may also be interested in...

PDUFA III “Good Review Management Principles” Stress Early FDA Action

FDA's "Good Review Management Principles" guidance will recognize the need to complete second- and third-round reviews of NDAs before the action goal date under the Prescription Drug User Fee Act III

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts